Trial Profile
Correlation of polymorphisms of JAK and STAT with gefitinib-induced hepatotoxicity in patients with non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2015
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic
- 21 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.